DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Coles AJ, Twyman CL, Arnold DL. , et al; CARE-MS II investigators.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Lancet 2012;
380 (9856): 1829-1839
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.